2021 SABCS Highlights
Dana-Farber Cancer Institute faculty highlights from the 2021 San Antonio Breast Cancer Symposium.
Dana-Farber Researchers Present Findings at San Antonio Breast Cancer Symposium
Researchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 44th annual San Antonio Breast Cancer Symposium on December 7-10th.
Tamoxifen May Boost PI3K Signaling to Increase Uterine Cancer Risk in Some Patients
Uterine cancers that developed in patients treated with tamoxifen had fewer PI3K pathway mutations and may have instead been driven by tamoxifen-induced PI3K pathway activation, according to results presented at the 2021 San Antonio Breast Cancer Symposium.
Adjuvant Palbociclib in HR+/HER2 Early Breast Cancer - Final results from PALLAS Trial
Dana-Farber's Erica Mayer, MD, MPH discusses the final analysis of the International Phase 3 PALLAS clinical trial presented at the 2021 San Antonio Breast Cancer Symposium.
Institute Physician
Assistant Professor of Medicine, Harvard Medical School
Assistant Professor of Medicine, Harvard Medical School
GS2-05 Update on the Combined TEXT and SOFT Trials
Dana-Farber's Meredith Regan, ScD presented an update on the SOFT/TEXT clinical trials at the 2021 San Antonio Breast Cancer Symposium.
Researcher